Research ArticleArticle
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard and Daniel B. Magilavy
The Journal of Rheumatology April 2013, 40 (4) 369-378; DOI: https://doi.org/10.3899/jrheum.120923
Michael E. Weinblatt
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA.
Arthur Kavanaugh
Mark C. Genovese
David A. Jones
Theresa K. Musser
Elliott B. Grossbard
REFERENCES
- ↵
- Boers M,
- Tugwell P,
- Felson DT,
- van Riel PL,
- Kirwan JR,
- Edmonds JP,
- et al.
- ↵
- Felson DT,
- Anderson JJ,
- Boers M,
- Bombardier C,
- Chernoff M,
- Fried B,
- et al.
- ↵
- ↵
- Kalyoncu U,
- Dougados M,
- Daures JP,
- Gossec L
- ↵
- Strand CV,
- Crawford B
- ↵
- ↵
- Carr AJ
- ↵
- ↵
- Gossec L,
- Dougados M,
- Rincheval N,
- Balanescu A,
- Boumpas DT,
- Canadelo S,
- et al.
- ↵
- ↵
- ↵
- Braselmann S,
- Taylor V,
- Zhao H,
- Wang S,
- Sylvain C,
- Baluom M,
- et al.
- ↵
- ↵
- ↵
- ↵
- ↵
- Cella D,
- Yount S,
- Sorensen M,
- Chartash E,
- Sengupta N,
- Grober J
- ↵
- Mease PJ,
- Revicki DA,
- Szechinski J,
- Greenwald M,
- Kivitz A,
- Barile-Fabris L,
- et al.
- ↵
- ↵
- ↵
- Ware JE Jr.,
- Kosinski M,
- Bjorner JB,
- Turner-Bowker DM,
- Gandek B,
- Maruish ME
- ↵
- ↵
- Aletaha D,
- Landewe R,
- Karonitsch T,
- Bathon J,
- Boers M,
- Bombardier C,
- et al.
- ↵
- Strand V,
- Burmester GR,
- Ogale S,
- Devenport J,
- John A,
- Emery P
- ↵
- ↵
- Strand V,
- Gajria K,
- Williams P,
- Barrett A,
- Fernandes A,
- Magrini F
- ↵
In this issue
The Journal of Rheumatology
Vol. 40, Issue 4
1 Apr 2013
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard, Daniel B. Magilavy
The Journal of Rheumatology Apr 2013, 40 (4) 369-378; DOI: 10.3899/jrheum.120923
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard, Daniel B. Magilavy
The Journal of Rheumatology Apr 2013, 40 (4) 369-378; DOI: 10.3899/jrheum.120923